Not Signed In -
Pituitary Gland |
|
|
Clinical Trial: The Treatment and Natural History of Acromegaly
This study is currently recruiting patients.
Purpose
The purpose of this study is to investigate the treatment and natural history of acromegaly. We have a longstanding interest in acromegaly treatment, and a cohort that has been followed for 30 years, or more in some cases. We will continue to follow patients and recruit new patients for treatment and follow-up. Blood and pituitary tumor tissue (when available through clinical care) will be saved for future analyses related to acromegaly.
| Condition |
|---|
| Acromegaly Pituitary Neoplasm |
MedlinePlus related topics: Bone Diseases; Brain Cancer; Brain Diseases; Cancer; Cancer Alternative Therapy; Endocrine Diseases; Pituitary Disorders
Study Type: Observational
Study Design: Natural History
Official Title: Acromegaly Treatment and Natural History
Expected Total Enrollment: 9999
Study start: April 15, 1985
The purpose of this study is to investigate the treatment and natural history of acromegaly. We have a longstanding interest in acromegaly treatment, and a cohort that has been followed for 30 years, or more in some cases. We will continue to follow patients and recruit new patients for treatment and follow-up. Blood and pituitary tumor tissue (when available through clinical care) will be saved for future analyses related to acromegaly.
Eligibility
Genders Eligible for Study: Both
Criteria
Patients will be enrolled who are 18 years of age or over who are referred for care. There are no exclusions.
Location and Contact Information
Maryland
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 9000 Rockville Pike, Bethesda, Maryland, 20892, United States; Recruiting
TTY 1-866-411-1010
More Information
Detailed Web Page
Publications
Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 1992 Sep;21(3):693-712. Review.
Gorden P, Comi RJ, Maton PN, Go VL. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989 Jan 1;110(1):35-50. Review.
Eastman RC, Arakaki RF, Shawker T, Schock R, Roach P, Comi RJ, Gorden P. A prospective examination of octreotide-induced gall-bladder changes in acromegaly. Clin Endocrinol (Oxf). 1992 Mar;36(3):265-9.
Record last reviewed: March 16, 2004
Last Updated: April 6, 2005
Record first received: January 21, 2000
ClinicalTrials.gov Identifier: NCT00001981
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
